Literature DB >> 33743013

Multi-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks.

Priska Stahel1, Changting Xiao2, Avital Nahmias1, Lili Tian1, Gary Franklin Lewis1.   

Abstract

Plasma triglyceride-rich lipoproteins (TRL), particularly atherogenic remnant lipoproteins, contribute to atherosclerotic cardiovascular disease. Hypertriglyceridemia may arise in part from hypersecretion of TRLs by the liver and intestine. Here we focus on the complex network of hormonal, nutritional, and neuronal interorgan communication that regulates secretion of TRLs and provide our perspective on the relative importance of these factors. Hormones and peptides originating from the pancreas (insulin, glucagon), gut [glucagon-like peptide 1 (GLP-1) and 2 (GLP-2), ghrelin, cholecystokinin (CCK), peptide YY], adipose tissue (leptin, adiponectin) and brain (GLP-1) modulate TRL secretion by receptor-mediated responses and indirectly via neural networks. In addition, the gut microbiome and bile acids influence lipoprotein secretion in humans and animal models. Several nutritional factors modulate hepatic lipoprotein secretion through effects on the central nervous system. Vagal afferent signaling from the gut to the brain and efferent signals from the brain to the liver and gut are modulated by hormonal and nutritional factors to influence TRL secretion. Some of these factors have been extensively studied and shown to have robust regulatory effects whereas others are "emerging" regulators, whose significance remains to be determined. The quantitative importance of these factors relative to one another and relative to the key regulatory role of lipid availability remains largely unknown. Our understanding of the complex interorgan regulation of TRL secretion is rapidly evolving to appreciate the extensive hormonal, nutritional, and neural signals emanating not only from gut and liver but also from the brain, pancreas, and adipose tissue.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adipose; brain; chylomicrons; gut peptides; pancreas; very-low density lipoproteins

Mesh:

Substances:

Year:  2021        PMID: 33743013      PMCID: PMC8599201          DOI: 10.1210/endrev/bnab008

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  185 in total

1.  Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins.

Authors:  Bolin Qin; Wei Qiu; Rita Kohen Avramoglu; Khosrow Adeli
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

2.  Glucagon-like peptide-2 mobilizes lipids from the intestine by a systemic nitric oxide-independent mechanism.

Authors:  Changting Xiao; Priska Stahel; Cecilia Morgantini; Avital Nahmias; Satya Dash; Gary F Lewis
Journal:  Diabetes Obes Metab       Date:  2019-08-19       Impact factor: 6.577

Review 3.  Recent Advances in Triacylglycerol Mobilization by the Gut.

Authors:  Changting Xiao; Priska Stahel; Alicia L Carreiro; Kimberly K Buhman; Gary F Lewis
Journal:  Trends Endocrinol Metab       Date:  2018-01-03       Impact factor: 12.015

4.  Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice.

Authors:  Joanne Hsieh; Karin E Trajcevski; Sarah L Farr; Christopher L Baker; Elizabeth J Lake; Jennifer Taher; Jahangir Iqbal; Mahmood M Hussain; Khosrow Adeli
Journal:  Endocrinology       Date:  2015-07-01       Impact factor: 4.736

5.  Glucagon regulates ACC activity in adipocytes through the CAMKKβ/AMPK pathway.

Authors:  I-Chen Peng; Zhen Chen; Wei Sun; Ying-Shiuan Li; Traci LaNai Marin; Pang-Hung Hsu; Mei-I Su; Xiaopei Cui; Songqin Pan; Christian Y Lytle; David A Johnson; Frank Blaeser; Talal Chatila; John Y-J Shyy
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-27       Impact factor: 4.310

6.  Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production.

Authors:  Penny Y T Wang; Liora Caspi; Carol K L Lam; Madhu Chari; Xiaosong Li; Peter E Light; Roger Gutierrez-Juarez; Michelle Ang; Gary J Schwartz; Tony K T Lam
Journal:  Nature       Date:  2008-04-09       Impact factor: 49.962

7.  Effects of Intracerebroventricular Administration of Neuropeptide Y on Metabolic Gene Expression and Energy Metabolism in Male Rats.

Authors:  Yan Su; Ewout Foppen; Eric Fliers; Andries Kalsbeek
Journal:  Endocrinology       Date:  2016-06-06       Impact factor: 4.736

8.  Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms.

Authors:  Elisabeth B Rüttimann; Myrtha Arnold; Jacquelien J Hillebrand; Nori Geary; Wolfgang Langhans
Journal:  Endocrinology       Date:  2008-10-23       Impact factor: 4.736

9.  Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids.

Authors:  Özlem Gögebakan; Janin Andres; Katrin Biedasek; Knut Mai; Peter Kühnen; Heiko Krude; Frank Isken; Natalia Rudovich; Martin A Osterhoff; Ulrich Kintscher; Michael Nauck; Andreas F H Pfeiffer; Joachim Spranger
Journal:  Diabetes       Date:  2011-12-16       Impact factor: 9.461

10.  Altered intestinal functions and increased local inflammation in insulin-resistant obese subjects: a gene-expression profile analysis.

Authors:  Alain Veilleux; Sylvain Mayeur; Jean-Christophe Bérubé; Jean-François Beaulieu; Eric Tremblay; Frédéric-Simon Hould; Yohan Bossé; Denis Richard; Emile Levy
Journal:  BMC Gastroenterol       Date:  2015-09-16       Impact factor: 3.067

View more
  1 in total

Review 1.  Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Authors:  Jan Borén; Marja-Riitta Taskinen; Elias Björnson; Chris J Packard
Journal:  Nat Rev Cardiol       Date:  2022-03-22       Impact factor: 49.421

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.